J&J settles Stelara issue with Teva, Alvotech

Johnson & Johnson (J&J) has settled with Teva and Alvotech over the biosimilar to its most lucrative asset, Stelara. The deal allows AVT04 to enter the US market no later than February 2025. This follows a May 2023 agreement with Amgen over ABP 654, which will hit markets no later than January 1, 2025. Stelara is a human IgG1k monoclonal antibody that targets the IL-12 and IL-23 cytokines. Its p..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 14.
  • textsms

FTC’s Challenge to Amgen-Horizon Merger Sparks Industry Attention

The Federal Trade Commission (FTC) is delaying the closure of Amgen's acquisition of Horizon Therapeutics, as both companies now aim to complete the merger by mid-December 2023. The FTC alleges that Amgen could use its drug portfolio to reinforce monopolistic positions for Horizon’s Tepezza and Krystexxa treatments where there are few competitors in these spaces. A federal court placed a tempora..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 8.
  • textsms